Stock Analiz

Immunocore Holdings plc (IMCR) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Immunocore Holdings’s revenue went from $30M in fiscal 2018 to $400M in fiscal 2025, growth of about 44.6% a year.

Net income in fiscal 2025 was -$36M, a net margin of -8.9%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $429M and net income -$32M.

Free cash flow was -$15M in fiscal 2025 and positive in 1 of the 8 years shown.

Revenue, profit and cash flow by year

Revenue
2018: $30M20182019: $34M20192020: $41M20202021: $36M20212022: $174M20222023: $249M20232024: $310M20242025: $400M2025$400M
Net income
2018: -$92M20182019: -$137M20192020: -$101M20202021: -$180M20212022: -$53M20222023: -$55M20232024: -$51M20242025: -$36M2025-$36M
Free cash flow
2018: -$26M20182019: -$141M20192020: -$88M20202021: -$144M20212022: -$51M20222023: -$2M20232024: $21M20242025: -$15M2025-$15M
EPS (diluted)
2018: $-1.7720182019: $-2.6620192020: $-1.9620202021: $-3.4820212022: $-1.0220222023: $-1.0720232024: $-0.9920242025: $-0.692025$-0.69

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$429M$400M$310M$249M$174M$36M$41M$34M$30M
Gross profit—$395M$307M$248M$173M$36M$41M——
Operating income—-$45M-$70M-$60M-$52M-$175M-$118M-$156M-$120M
Net income-$32M-$36M-$51M-$55M-$53M-$180M-$101M-$137M-$92M
EPS (diluted)$-0.63$-0.69$-0.99$-1.07$-1.02$-3.48$-1.96$-2.66$-1.77
R&D—$275M$222M$164M$102M$100M———
Revenue growth—+28.9%+24.4%+43.0%+377.9%−11.2%+21.3%+11.9%—

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow-$10M-$11M$26M$3M-$49M-$143M-$84M-$136M-$21M
Capital spending-$8M-$4M-$5M-$5M-$2M-$1M-$4M-$5M-$4M
Free cash flow-$18M-$15M$21M-$2M-$51M-$144M-$88M-$141M-$26M
Dividends paid—$0$0$0$0$0$0$0$0
Buybacks—————————
Stock-based pay—$38M$34M$32M$33M$49M$11M$4M$852480

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$864M$820M$443M$402M$321M$177M$98M$159M
Debt—$44M$42M$36M$81M$50M$50M$25M—
Equity—$381M$361M$369M$339M$234M$77M$20M$72M
Total assets—$1.1B$1.0B$597M$527M$407M$269M$245M—
Shares (diluted)51M52M52M52M52M52M52M52M52M

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin—98.7%99.1%99.6%99.4%100.0%100.0%——
Operating margin—-11.3%-22.7%-23.9%-29.7%-478.5%-286.2%-460.9%-395.1%
Net margin-7.5%-8.9%-16.5%-22.2%-30.1%-493.4%-246.0%-404.9%-302.8%
FCF margin-4.2%-3.8%6.7%-1.0%-29.5%-396.0%-213.6%-416.8%-85.0%
ROIC—-8.4%-16.9%-13.4%-9.7%-48.6%-78.6%-287.2%-134.2%
ROE—-9.3%-14.2%-15.0%-15.5%-77.0%-131.5%-703.6%-126.6%

Frequently asked questions

What is Immunocore Holdings’s annual revenue?

$400M in fiscal 2025 and $429M over the twelve months to September 30, 2026.

How much profit does Immunocore Holdings make?

Net income was -$36M in fiscal 2025 (net margin -8.9%).

Is Immunocore Holdings’s revenue growing?

Yes: revenue rose 29.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.